Please rate this video

ICML 2019 | ALPINE results: zanubrutinib vs. ibrutinib in CLL

Please rate this video

Constantine Tam

The ALPINE study (NCT03734016) investigated zanubrutinib vs. ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results thus far from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter